LLY

1,136.41

-0.5%↓

JNJ

238.85

+0.91%↑

ABBV

225.29

+0.05%↑

UNH

407.06

-1.28%↓

MRK

119

-0.38%↓

LLY

1,136.41

-0.5%↓

JNJ

238.85

+0.91%↑

ABBV

225.29

+0.05%↑

UNH

407.06

-1.28%↓

MRK

119

-0.38%↓

LLY

1,136.41

-0.5%↓

JNJ

238.85

+0.91%↑

ABBV

225.29

+0.05%↑

UNH

407.06

-1.28%↓

MRK

119

-0.38%↓

LLY

1,136.41

-0.5%↓

JNJ

238.85

+0.91%↑

ABBV

225.29

+0.05%↑

UNH

407.06

-1.28%↓

MRK

119

-0.38%↓

LLY

1,136.41

-0.5%↓

JNJ

238.85

+0.91%↑

ABBV

225.29

+0.05%↑

UNH

407.06

-1.28%↓

MRK

119

-0.38%↓

Strona główna・Stock List・Zai Lab Ltd ADR
Search

Zai Lab Ltd ADR

Closed

SectorHealthcare

17.23 3.8

Strong Buy

Price update 10 cze 2026, 19:59 UTC

BuySell

Overview

Share price change

24h

Current

Min

16.63

Max

17.83

Key metrics

By Trading Economics

Income

-607K

-51M

Sales

-28M

100M

EPS

-0.46

Profit margin

-51.215

Employees

1,784

EBITDA

4.1M

-44M

Recommendations

By TipRanks

Recommendations

Strong Buy

12 Months Forecast

+94.59% upside

Dividends

By Dow Jones

Next Earnings

6 sie 2026

Market Stats

By TradingEconomics

Market Cap

-516M

1.9B

Previous open

13.43

Previous close

17.23

News Sentiment

By Acuity

16%

84%

29 / 344 Ranking in Healthcare

Zai Lab Ltd ADR Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

10 cze 2026, 23:36 UTC

Earnings

Correction to Oracle Reports Higher 4Q Profit Article

DJ

Read

10 cze 2026, 23:19 UTC

Hot Stocks

Stocks to Watch: Oracle, Oxford Industries, Humacyte, PureCycle Technologies

DJ

Read

10 cze 2026, 23:09 UTC

Major Market Movers

PureCycle Technologies Slides on Offerings of Stock and Convertible Notes

DJ

Read

10 cze 2026, 23:04 UTC

Earnings

Oracle Reports Higher 4Q Profit on Surging Cloud Revenue -- Update

DJ

Read

10 cze 2026, 20:44 UTC

Major Market Movers

Caterpillar Raises Quarterly Dividend 8%

DJ

Read

10 cze 2026, 23:49 UTC

Acquisitions, Mergers, Takeovers

Elliott: Northern Star Should Take No Options Off The Table

DJ

Read

10 cze 2026, 23:48 UTC

Acquisitions, Mergers, Takeovers

Elliott: Reiterates Call For Formal Strategic Review of Northern Star

DJ

Read

10 cze 2026, 23:48 UTC

Acquisitions, Mergers, Takeovers

Elliott: Northern Star Board Must Be Substantially Strengthened Beyond 1 Additional Director

DJ

Read

10 cze 2026, 23:47 UTC

Market Talk

Nintendo's Stock Recovery Likely Deferred Without Mario Game -- Market Talk

DJ

Read

10 cze 2026, 23:47 UTC

Acquisitions, Mergers, Takeovers

Elliott: Board Letter Indicates It Doesn't Understand Magnitude of Change Required

DJ

Read

10 cze 2026, 23:46 UTC

Acquisitions, Mergers, Takeovers

Elliott Investment Management: Northern Star Letter Validates Investment Thesis

DJ

Read

10 cze 2026, 23:38 UTC

Market Talk

Global Equities Roundup: Market Talk

DJ

Read

10 cze 2026, 23:38 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

DJ

Read

10 cze 2026, 23:38 UTC

Market Talk

Nikkei Likely to Fall on Renewed Concerns About Iran Conflict -- Market Talk

DJ

Read

10 cze 2026, 23:32 UTC

Market Talk

Oil Rises Amid Escalating Supply-Disruption Fears -- Market Talk

DJ

Read

10 cze 2026, 23:20 UTC

Market Talk

Wesfarmers's Bunnings Business Looks Resilient to Macro Headwinds -- Market Talk

DJ

Read

10 cze 2026, 22:05 UTC

Market Talk

Correction to Bank of Canada Stays on Hold Market Talk

DJ

Read

10 cze 2026, 21:57 UTC

Earnings

Oracle Stock Slides on Mixed Earnings. Software Is an Issue. -- Barrons.com

DJ

Read

10 cze 2026, 21:52 UTC

Earnings

Oracle Stock Slides on Mixed Earnings. Software Is an Issue. -- Barrons.com

DJ

Read

10 cze 2026, 21:35 UTC

Earnings

Oracle Stock Slides on Mixed Earnings. Software Is an Issue. -- Barrons.com

DJ

Read

10 cze 2026, 21:22 UTC

Earnings

Oracle Stock Slides on Increased Capital Spending -- WSJ

DJ

Read

10 cze 2026, 20:50 UTC

Market Talk
Earnings

Tech, Media & Telecom Roundup: Market Talk

DJ

Read

10 cze 2026, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

DJ

Read

10 cze 2026, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

DJ

Read

10 cze 2026, 20:50 UTC

Market Talk

Health Care Roundup: Market Talk

DJ

Read

10 cze 2026, 20:39 UTC

Market Talk
Earnings

Oracle Needs to Raise Less Capital to Fund Data-Center Buildout -- Market Talk

DJ

Read

10 cze 2026, 20:34 UTC

Earnings

Oracle Stock Slides on Mixed Earnings. Software Is an Issue. -- Barrons.com

DJ

Read

10 cze 2026, 20:33 UTC

Earnings

This 'Amazon for Travel' Firm Beat Earnings Expectations. The Stock Is Soaring. -- Barrons.com

DJ

Read

10 cze 2026, 20:33 UTC

Market Talk
Earnings

Global Equities Roundup: Market Talk

DJ

Read

10 cze 2026, 20:33 UTC

Market Talk
Earnings

Oracle Health Expected to Grow Double-Digits This Fiscal Year -- Market Talk

DJ

Read

Peer Comparison

Price change

Zai Lab Ltd ADR Forecast

Price Target

By TipRanks

94.59% upside

12 Months Forecast

Average 32.4 USD  94.59%

High 44 USD

Low 21.6 USD

Based on 4 Wall Street analysts offering 12 month price targets forZai Lab Ltd ADR - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

4 ratings

3

Buy

1

Hold

0

Sell

Based on 4 analysts giving stock ratings to Zai Lab Ltd ADR - Dist in the past 3 months.

Sentiment

By Acuity

29 / 344 Ranking in Healthcare

News Sentiment

Very Strong Bullish Evidence

Volatility

Below average

News Volume (RCV)

Below average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Zai Lab Ltd ADR

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis. The company also develops Tumor Treating Fields, a portable device for delivery of electric fields; Repotrectinib, a tyrosine kinase inhibitor (TKI) to target ROS1 and TRK A/B/C in TKI-naïve- or -pretreated cancer patients; Tisotumab vedotin, an antibody drug conjugate; Adagrasib for treating KRAS-G12C-mutated NSCLC, colorectal cancer, and pancreatic cancer; and Bemarituzumab to treat gastric and gastroesophageal junction cancer patients. In addition, it develops Sulbactam/durlobactam, a combination of a beta-lactam antibiotic and a beta-lactamase inhibitor for the treatment of serious infections caused by Acinetobacter; KarXT for the treatment of psychiatric and neurological conditions. It has license and collaboration agreement with Tesaro, Inc. to develop, manufacture, and commercialize niraparib; NovoCure to develop and commercialize Tumor Treating Fields; Deciphera to develop and commercialize ripretinib; Paratek Bermuda Ltd. to develop, manufacture, and commercialize omadacycline; argenx, to develop and commercialize efgartigimod; BMS to develop and commercialize tisotumab vedotin and repotrectinib; Mirati to research, develop, manufacture, and commercialize adagrasib; Amgen to develop and commercialize bemarituzumab; and Innoviva to develop and commercialize Sulbactam-Durlobactam; Karuna to develop and commercialize KarXT; and strategic collaboration with Pfizer for XACDURO. The company was incorporated in 2013 and is headquartered in Shanghai, China.

Other stocks from the sector

LLY

Eli Lilly and Co.

1,136.41

↓-0.5%

JNJ

Johnson and Johnson

238.85

↑ +0.91%

ABBV

AbbVie Inc

225.29

↑ +0.05%

UNH

UnitedHealth Group Inc

407.06

↓-1.28%

MRK

Merck & Co Inc.

119

↓-0.38%
help-icon Live chat